BLISS GVS PHARMA LTD. - 506197 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that our Registrar and Share Transfer Agent of the Company M/s. Link Intime India Pvt. Ltd have received a request to issue of duplicate share certificate consequent to loss of share certificate from the shareholder. BLISS GVS PHARMA LTD. - 506197 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Enclosed herewith a certificate received from Link Intime India Pvt. Ltd, Registrar and Share Transfer Agent of the Company under Regulation 74(5) of the Securities and Exchnage Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2023. BLISS GVS PHARMA LTD. - 506197 - Intimation Of Merger Of Universal Capital Securities Private Limited With Link Intime India Private Limited
This is to inform you that the Company''s Registrar and Share Transfer Agent ("RTA") formerly known as Universal Capital Securities Private Limited has merged with Link Intime India Private Limited effective December 22, 2023. Enclosed herewith Intimation in this regard. BLISS GVS PHARMA LTD. - 506197 - Closure of Trading Window
This is to inform you that pursuant to the Securities Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force) and in accordance with the Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons, the Trading window for dealing in securities/shares of Bliss GVS Pharma Limited ("the Company")shall remain closed for all Designated Persons and their immediate realtives of the Company with effect from January 01, 2024 till completion of 48 hours after the announcement of the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2023 generally made available to the public. BLISS GVS PHARMA LTD. - 506197 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that our Registrar and Share Transfer Agent of Company M/s. Universal Capital Securities Private Limited have received a request to issue of duplicate share certificate consequent to loss share certificate from the shareholder. BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to the provision of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the copies of newspaper advertisement published regarding extract of the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2023, "The Economic Times & The Free Press Journal" an English Daily and "Maharashtra Times & Navshakti" a Regional Daily, on November 03, 2023. BLISS GVS PHARMA LTD. - 506197 - Board Meeting Outcome for Outcome Of Board Meeting Held On Wednesday, November 01, 2023
We would like to inform you that the Board Meeting of the Company was held today i.e. Wednesday, November 01, 2023, at the registered office of the Company. In pursuant to Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has considered and approved the following matters amongst others: 1. The Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2023. 2. Investment of INR 30 Crores (Approx.) for Capacity Addition/Inclusion of Semi-Solids Finished formulation at our Palghar Vevoor Unit. The Total Capacity expected is approx. 200 million Units in Semi-Solids Dosage and that is expected to be completed and available for commercial production by end of F. Y 2025-26. This expansion shall be funded by a combination of debt and internal accrual. BLISS GVS PHARMA LTD. - 506197 - Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2023
We would like to inform you that the Board Meeting of the Company was held today i.e. Wednesday, November 01, 2023, at the registered office of the Company. In pursuant to Regulation 30 and Regulation 33 read with Schedule III of SEBI Listing Regulations. Enclosed herewith Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2023 along with Limited Review Report. BLISS GVS PHARMA LTD. - 506197 - Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year September 30, 2023
BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/11/2023 ,inter alia, to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year September 30, 2023. Further, pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons, the trading window for dealing in shares of the Company was closed for all the Designated Persons of the Company and their immediate relatives of the Company from October 01, 2023 and shall remain closed until 48 hours after the announcement of unaudited Financial Results of the Company for the quarter and half year September 30, 2023. BLISS GVS PHARMA LTD. - 506197 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Registrar and Share Transfer Agent of Company M/s. Universal Capital Securities Private Limited have received a request to issue of duplicate share certificate consequent to loss of share certifcate from the shareholder.